Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. Earnings Recaps

CAPR Health Care 2 recaps
Next earnings: March 11, 2027 (estimated) · full calendar
Q3 2026 Nov 12, 2026

Capricorn Therapeutics shares rose 26.5% after the earnings call, as investors responded to the company’s account of positive HOPE-3 efficacy data and its view that the FDA review is nearing completion. The BLA remains under review, with the agency’s target action date extended to November 22.

Key takeaways
  • Capricorn said HOPE-3 met its primary endpoint: the 1-year difference on the Performance of the Upper Limb 2.0 was 1.1 points versus placebo (p=0.029), which management characterized as clinically meaningful.
  • In the 24-month open-label extension, patients who switched from placebo to deramiocel saw their annual decline slow from about 2 points to about 0.5 points; the company described these results as supportive but noted they are descriptive.
  • Cardiac results were mixed: deramiocel slowed progression of heart muscle scarring, while the overall ejection-fraction difference versus placebo was not statistically significant. In the prespecified subgroup with existing cardiomyopathy, ejection fraction improved by approximately 2.8 percentage points relative to placebo.
  • The FDA is reviewing an August BLA amendment that included 24-month HOPE-3 data and additional analyses. Capricorn said all requested information has been submitted; the review is ongoing.
  • Management said the proposed refined indication focuses on treatment of upper-limb impairment in patients older than 9 years.
Q3 2025 Nov 11, 2025

Capricor Therapeutics reported significant advancements ahead of the anticipated results from the pivotal HOPE-3 Phase 3 study of Daramycin, targeting Duchenne muscular dystrophy, bolstered by a robust safety profile demonstrated across a significant patient population.

Key takeaways
  • The HOPE-3 study, involving 105 participants, marks one of the largest double-blind trials in Duchenne muscular dystrophy, focusing on non-ambulant patients.
  • Safety data from over 800 infusions indicate a consistent safety profile with no new safety signals reported, aligning with the company's commitment to patient safety.
  • The company plans to submit HOPE-3 results to address FDA feedback following a Complete Response Letter (CRL) received in July, which stipulated the need for additional evidence of efficacy.
  • The FDA has classified the resubmission for Daramycin as Type 2, potentially expediting the review process ahead of a new PDUFA date in 2026.
  • Capricor has positioned itself to address unmet medical needs related to Duchenne muscular dystrophy-associated cardiomyopathy, a leading cause of mortality in affected patients.